Back to top
more

vTv Therapeutics (VTVT)

(Delayed Data from NSDQ)

$25.77 USD

25.77
1,576

+0.27 (1.06%)

Updated Apr 25, 2024 03:59 PM ET

After-Market: $25.39 -0.38 (-1.47%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

VTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of 23.64% and 4.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and vTv Therapeutics (VTVT) have performed compared to their sector so far this year.

Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA

by Zacks Equity Research

The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.

Intellia (NTLA) Inks Deal With Kyverna for Autoimmune Diseases

by Zacks Equity Research

Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.

Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag

by Zacks Equity Research

The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.

Apellis (APLS) Up More Than 40% in Past 3 Months: Here's Why

by Zacks Equity Research

Approval of Apellis' (APLS) Empaveli for treating paroxysmal nocturnal hemoglobinuria lends a significant boost to the company's growth prospects. The drug's label expansion studies also hold promise.

Kodiak Sciences (KOD) Focuses on Developing Eye Candidate KSI-301

by Zacks Equity Research

Kodiak Sciences (KOD) progresses well with the development of its lead candidate, KSI-301, for treating various retinal vascular diseases. Stiff competition in the target market remains a woe.

Palatin (PTN) Begins Phase III Study For Dry Eye Disease

by Zacks Equity Research

Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.

ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA

by Zacks Equity Research

ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis. Shares rise.

Global Blood (GBT) Gets FDA Nod for Oxbryta Label Expansion

by Zacks Equity Research

The FDA approves Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to less the 12 years, and NDA for a pediatric weight-based formulation of the drug.

Bristol Myers' (BMY) Orencia Gets FDA Nod for New Indication

by Zacks Equity Research

The FDA approves Bristol Myers' (BMY) Orencia in combination with a calcineurin inhibitor and methotrexate to prevent acute graft versus host disease. This is the fourth FDA-approved indication for the drug.

Alnylam (ALNY) Files for Oxlumo Label Expansion in US & EU

by Zacks Equity Research

Alnylam (ALNY) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.

Trevena (TRVN) to Begin Clinical Study on Pain Candidate

by Zacks Equity Research

Trevena (TRVN) advances TRV045 into clinical development as a potential treatment for diabetic neuropathic pain. Enrollment in the study is expected to begin in the first quarter of 2022.

Cytokinetics' (CYTK) Aficamten Gets Breakthrough Therapy Tag

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy status on Cytokinetics' (CYTK) aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Intercept (ICPT) Down on Withdrawal of Application for NASH

by Zacks Equity Research

Intercept (ICPT) withdraws its application seeking approval for OCA for the treatment of liver fibrosis due to nonalcoholic steatohepatitis in the EU. Resultantly, the stock declines.

Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Aytu BioPharma's (AYTU) AR101 for the treatment of vascular Ehlers-Danlos Syndrome.

Here's Why vTv Therapeutics (VTVT) is Poised for a Turnaround After Losing 15.2% in 4 Weeks

by Zacks Equity Research

vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Ultragenyx (RARE) Begins Dosing in Phase I/II Study of UX053

by Zacks Equity Research

Ultragenyx (RARE) doses the first patient in a phase I/II study evaluating its investigational mRNA candidate, UX053, for treating glycogen storage disease type III.

Deciphera (DCPH) to Prioritize Key Pipeline Drugs, Cut Jobs

by Zacks Equity Research

Deciphera (DCPH) announces a corporate restructuring plan to prioritize development of vimseltinib and DCC-3116, streamline commercial operations and reduce workforce by almost 35%. Shares rise.

    Blueprint Medicines (BPMC) Set to Acquire Lengo Therapeutics

    by Zacks Equity Research

    Blueprint Medicines (BPMC) inks an agreement to acquire privately held Lengo Therapeutics. The company is looking to boost its lung cancer portfolio with this acquisition.

    BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930

    by Zacks Equity Research

    BioCryst (BCRX) starts patient enrollment in the pivotal REDEEM-2 study evaluating BCX9930 for treating patients with paroxysmal nocturnal hemoglobinuria.

    Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study

    by Zacks Equity Research

    The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.

    Coherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare Cancer

    by Zacks Equity Research

    The FDA bestows an Orphan Drug designation to Coherus (CHRS) and partner Junshi's toripalimab for the treatment of esophageal cancer.